Chlamydia infection medical therapy

Jump to navigation Jump to search

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Monalisa Dmello, M.B,B.S., M.D. [2], Aysha Anwar, M.B.B.S[3]

Sexually transmitted diseases Main Page

Chlamydia infection Microchapters

Home

Patient Information

Overview

Historical Perspective

Pathophysiology

Causes

C. trachomatis
Other Chlamydiae

Differentiating Chlamydia Infection from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Ultrasound

Other Imaging Findings

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Chlamydia infection medical therapy On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Chlamydia infection medical therapy

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Chlamydia infection medical therapy

CDC on Chlamydia infection medical therapy

Chlamydia infection medical therapy in the news

Blogs on Chlamydia infection medical therapy

Directions to Hospitals Treating Chlamydia infection

Risk calculators and risk factors for Chlamydia infection medical therapy

Overview

The mainstay of therapy for chlamydia is antimicrobial therapy with doxycycline. Recent sex partners (i.e., individuals having sexual contact with the patient within the 60 days preceding onset of symptoms or chlamydia diagnosis) should also be referred for evaluation, testing, and treatment.

Medical Therapy

  • Chlamydia infection treatment is recommended for all the persons who test positive to prevent complications.[1][2]

Antimicrobial Regimen

  • 1.1 Chlamydial Infections in adolescents and adults
  • Preferred regimen (1): Doxycycline 100 mg PO bid for 7 days[5]
  • Alternative regimen (1): Azithromycin 1 g PO in a single dose[6][5]
  • Alternative regimen (2): Levofloxacin 500 mg PO qd for 7 days[5]
  • Alternative regimen (3): Erythromycin base 500 mg PO qid for 7 days
  • Alternative regimen (4): Erythromycin ethylsuccinate 800 mg PO qid for 7 days
  • Alternative regimen (5): Ofloxacin 300 mg PO bid for 7 days
  • Note: Patients should be instructed to refer their sex partners for evaluation, testing, and treatment if they had sexual contact with the patient during the 60 days preceding onset of the patient's symptoms or chlamydia diagnosis. Sex abstinence is recommended for 7 days or till resolution of symptoms
  • 1.2 Chlamydial Infections in patients with HIV Infection
  • Preferred regimen (1): Doxycycline 100 mg PO bid for 7 days
  • Preferred regimen (2): Azithromycin 1 g PO in a single dose
  • Preferred regimen (3): Azithromycin 1 g PO in a single dose
  • Alternative regimen (1): Erythromycin base 500 mg PO qid for 7 days
  • Alternative regimen (2): Erythromycin ethylsuccinate 800 mg PO qid for 7 days
  • Alternative regimen (3): Levofloxacin 500 mg PO qd for 7 days
  • Alternative regimen (4): Ofloxacin 300 mg PO bid for 7 days
  • 1.3 Pregnancy
  • 1.4 Management of sex partners
  • Preferred regimen (1): Doxycycline 100 mg PO bid for 7 days
  • Preferred regimen (2): Azithromycin 1 g PO in a single dose
  • Alternative regimen (1): Erythromycin base 500 mg PO qid for 7 days
  • Alternative regimen (2): Erythromycin ethylsuccinate 800 mg PO qid for 7 days
  • Alternative regimen (3): Levofloxacin 500 mg PO qd for 7 days
  • Alternative regimen (4): Ofloxacin 300 mg PO bid for 7 days
  • Note (1): Recent sex partners (i.e., persons having sexual contact with the infected patient within the 60 days preceding onset of symptoms or Chlamydia diagnosis) should be referred for evaluation, testing, and presumptive dual treatment.
  • Note (2): If the patient’s last potential sexual exposure was >60 days before onset of symptoms or diagnosis, the most recent sex partner should be treated.[1]
  • Note (3): To avoid reinfection, sex partners should be instructed to abstain from unprotected sexual intercourse for 7 days after they and their sexual partner(s) have completed treatment and after resolution of symptoms, if present.
  • 2. Chlamydial infection among neonates
  • 2.1 Ophthalmia Neonatorum caused by C. trachomatis
  • Preferred regimen: Erythromycin base or ethylsuccinate 50 mg/kg/day PO qid for 14 days[5]
  • Alternative regimen: Azithromycin suspension 20 mg/kg /day PO qd for 3 days[9]
  • Note: The mothers of infants who have chlamydial infection and the sex partners of these women should be evaluated and treated.
  • 2.2 Infant Pneumonia
  • 3.Chlamydial infection among infants and children
  • 3.1 Infants and children who weigh < 45 kg
  • Preferred regimen: Erythromycin base or ethylsuccinate 50 mg/kg/ day PO qid for 14 days[5]
  • 3.2 Infants and children who weigh ≥45 kg but who are aged <8 years
  • 3.3 Infants and children aged ≥8 years
  • 4. Lymphogranuloma venereum (LGV) [3]
  • Preferred regimen: Doxycycline 100 mg PO bid for 21 days
  • Alternative regimen: Erythromycin base 500 mg PO qid for 21 days
  • Note (1): Azithromycin 1 g PO once weekly for 3 weeks is probably effective based on its chlamydial antimicrobial activity. Fluoroquinolone-based treatments might also be effective, but extended treatment intervals are likely required.
  • Note (2): Pregnant and lactating women should be treated with Erythromycin. Azithromycin might prove useful for treatment of LGV in pregnancy, but no published data is available regarding its safety and efficacy. Doxycycline is contraindicated in pregnant women.
  • Note (3): Persons with both LGV and HIV infection should receive the same regimens as those who are HIV negative. Prolonged therapy might be required, and delay in resolution of symptoms might occur.
  • Note (4): Persons who have had sexual contact with a patient who has LGV within the 60 days before onset of the patient’s symptoms should be examined and tested for urethral, cervical, or rectal chlamydial infection depending on anatomic site of exposure. They should be presumptively treated with a chlamydia regimen ( Azithromycin 1 g PO single dose OR Doxycycline 100 mg PO bid for 7 days).

Follow-up guidelines

  • Resting for positive cases after 3 months of treatment[10][11]
  • Resting within 12 months after treatment if patient fails to follow up in 3 months period.[1]
  • Infants with ophthalmia neonatorum needs a follow up testing as treatment efficacy erythromycin is not more than 80%.[1]
  • In sexual abuse of children and adults, repeat testing should be performed after 2 weeks of treatment.
  • All pregnant women diagnosed with chlamydia infection should be retested 3-4 weeks after treatment.
  • All pregnant women are retested 3 months after initial infection.[12]

References

  1. 1.0 1.1 1.2 1.3 1.4 http://www.cdc.gov/std/tg2015/chlamydia.htm Accessed on September 14,2016
  2. Geisler, William M., et al. "The natural history of untreated Chlamydia trachomatis infection in the interval between screening and returning for treatment." Sexually transmitted diseases 35.2 (2008): 119-123.
  3. 3.0 3.1 Workowski, Kimberly A.; Bolan, Gail A. (2015-06-05). "Sexually transmitted diseases treatment guidelines, 2015". MMWR. Recommendations and reports: Morbidity and mortality weekly report. Recommendations and reports / Centers for Disease Control. 64 (RR-03): 1–137. ISSN 1545-8601. PMID 26042815.
  4. Lau, Chuen-Yen, and Azhar K. Qureshi. "Azithromycin versus doxycycline for genital chlamydial infections: a meta-analysis of randomized clinical trials." Sexually transmitted diseases 29.9 (2002): 497-502.
  5. 5.00 5.01 5.02 5.03 5.04 5.05 5.06 5.07 5.08 5.09 5.10 5.11 Workowski KA, Bachmann LH, Chan PA, Johnston CM, Muzny CA, Park I; et al. (2021). "Sexually Transmitted Infections Treatment Guidelines, 2021". MMWR Recomm Rep. 70 (4): 1–187. doi:10.15585/mmwr.rr7004a1. PMC 8344968 Check |pmc= value (help). PMID 34292926 Check |pmid= value (help).
  6. Hathorn, Emma, Catherine Opie, and Penny Goold. "What is the appropriate treatment for the management of rectal Chlamydia trachomatis in men and women?." Sexually transmitted infections 88.5 (2012): 352-354.
  7. Jacobson, Gavin F., et al. "A randomized controlled trial comparing amoxicillin and azithromycin for the treatment of Chlamydia trachomatis in pregnancy." American journal of obstetrics and gynecology 184.7 (2001): 1352-1356.
  8. Kacmar, Jennifer, et al. "A randomized trial of azithromycin versus amoxicillin for the treatment of Chlamydia trachomatis in pregnancy." Infectious diseases in obstetrics and gynecology 9.4 (2001): 197-202.
  9. Hammerschlag, Margaret R., et al. "Treatment of neonatal chlamydial conjunctivitis with azithromycin." The Pediatric infectious disease journal 17.11 (1998): 1049-1050.
  10. Fung, Monica, et al. "Chlamydial and gonococcal reinfection among men: a systematic review of data to evaluate the need for retesting." Sexually transmitted infections 83.4 (2007): 304-309.
  11. Hosenfeld, Christina B., et al. "Repeat infection with Chlamydia and gonorrhea among females: a systematic review of the literature." Sexually transmitted diseases 36.8 (2009): 478-489.
  12. Hood, Ellie E., and Robert C. Nerhood. "The utility of screening for chlamydia at 34-36 weeks gestation." West Virginia Medical Journal 106.6 (2010): 10-12.


Template:WikiDoc Sources